MAP2K7 and neoplasm: Surprisingly, treatment with an anti-CCL2 antibody of KPC tumors treated with MEK and CDK4/6 inhibitors, along with an EZH2 blockade, led to a significant reduction in anti-tumor effects, highlighting that NK cell accumulation was critical for tumor regression [130].